The benchmark MSCI Green Energy Index jumped 2% after China’s April renewable output rose 14% year-over-year, a positive signal for globally traded green investing companies. The business may end up looking a whole lot different over the next five-plus years. While its fundamentals still look good (it generated nearly $11 billion in profits over the trailing 12 months), investors are hesitant about whether or not they can trust this struggling stock, especially amid such uncertain times in the healthcare sector. manager to incorrectly assess an investment’s ESG characteristics or performance. Such data or information may be obtained through voluntary or third-party reporting. Morgan Stanley does not verify that such information and data is accurate and makes no representation or warranty as to its accuracy, timeliness, or completeness when evaluating an issuer. This can cause Morgan Stanley to incorrectly assess an issuer’s business practices with respect to its ESG practices. As a result, it is difficult to compare ESG investment products. Price-to-earnings ratios for leading green investing companies now average 28x, slightly above the sector’s five-year median, indicating that investors are paying a premium for anticipated growth acceleration.